Company News

Lysoway Therapeutics appoints Chris Adams, PhD to its board of directors

Cambridge, MA, April 2, 2024 – Lysoway Therapeutics, a leading discovery-stage biotech company dedicated to developing next-generation treatments for patients with neurodegenerative diseases, today proudly announces the appointment of Chris Adams, PhD to its board of directors. Dr. Adams brings a wealth of experience as a distinguished business leader, entrepreneur and mentor, with a proven track record of guiding biotechnology companies towards maximizing program value and realizing their full potential.

“We are thrilled to welcome Chris to the Lysoway board of directors as we advance our pipeline into clinical studies next year,” said Yongchang Qiu, CEO & President, Co-Founder of Lysoway Therapeutics. “Chris’s extensive industry expertise and strategic guidance will be invaluable to Lysoway as we bolster our team and navigate key milestones in 2024 and beyond.”

Dr. Adams is a strategic biotech executive with over three decades of broad cross-functional expertise spanning all facets of biotech operations. His impressive background includes in-depth experience with start-up operations, fundraising, M&A, business development, strategic transactions, and company building. In 2013, he co-founded Cydan, an orphan drug accelerator focused on improving the lives of patients with rare genetic diseases. Together with the Cydan team, he successfully raised over $200M and co-founded  and served on the Board of three startups: Vtesse, Imara and Tiburio. Prior to Cydan, he served as the Chief Business Officer of FoldRx Pharmaceuticals Inc., where he played a pivotal role in the development of VYNDAQEL® (tafamidis) for TTR amyloidosis, leading to its acquisition by Pfizer in 2010. Previously, he held various business development and marketing roles at  ViaCell Inc., TKT Inc. and Ciba-Geigy AG. Currently Dr. Adams serves on the Board of Directors of Alkeus Pharmaceuticals Inc., Aviceda Therapeutics Inc. and Reveal Pharmaceuticals Inc. He holds a PhD in organic chemistry and a diploma in organic chemistry and biochemistry from the University of Zurich, and an MBA from INSEAD of Fontainebleau, France.

“It is a privilege to join Lysoway’s board as the organization advances towards delivering new treatment options for patients with neurodegenerative diseases, many of whom have been significantly underserved for decades,” said Dr. Adams “I look forward to working alongside this team and advancing a promising pipeline through development and towards the market.”

About Lysoway Therapeutics

Lysoway Therapeutics is a leader in lysosomal ion channel disease biology. We have developed unique technological approaches to screen and develop potent modulators of lysosomal ion channels, including TRPML1 and TMEM175. These ion channels serve as vital transducers of cellular signals and play crucial roles in maintaining cellular homeostasis, particularly within the autophagy/lysosomal pathway, which is frequently disrupted in a number of pathological conditions. Lysoway’s small molecule modulators hold immense potential for restoring autophagy/lysosomal function, offering potential treatment for neurodegenerative diseases associated with lysosomal deficiency and other rare diseases characterized by toxic accumulation of cellular wastes.

Contact Info